JOHNSON & JOHNSON
JNJ
51 insider filings · Latest: Aug 13, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 14 8:35 PM | Joaquin DuatoDirector, CEO and Chairman of the Board | Sale | 123,291 | $261.17 | $32.2M | 275,967(D) | View → |
| Aug 13, 2026 | Aug 13 6:12 PM | Duato Joaquin | Proposed Sale | 123,291 | $261.17 | $32.2M | — | View → |
| Aug 5, 2026 | Aug 7 9:50 PM | Joaquin DuatoDirector, CEO and Chairman of the Board | Sale | 48,480 | $258.15 | $12.5M | 275,967(D) | View → |
| Aug 6, 2026 | Aug 7 9:44 PM | Elizabeth ForminardEVP, Chief Legal Officer | Sale | 15,918 | $257.00 | $4.1M | 16,994(D) | View → |
| Aug 6, 2026 | Aug 6 6:02 PM | Forminard Elizabeth | Proposed Sale | 15,918 | $257.00 | $4.1M | — | View → |
| Aug 5, 2026 | Aug 5 10:07 PM | Joaquin Duato | Proposed Sale | 48,480 | $254.93 | $12.4M | — | View → |
| Jul 20, 2026 | Jul 21 9:27 PM | Vanessa BroadhurstEVP, Global Corp Affairs | Sale | 23,054 | $251.27 | $5.8M | 23,003(D) | View → |
| Jul 20, 2026 | Jul 20 5:35 PM | Broadhurst Vanessa | Proposed Sale | 23,054 | $251.27 | $5.8M | — | View → |
| Jun 11, 2026 | Jun 12 9:23 PM | Kathryn E WengelEVP, Chief TO and Risk Officer | Sale | 10,000 | $241.15 | $2.4M | 114,287.874(D) | View → |
| Jun 11, 2026 | Jun 11 5:44 PM | Wengel Kathryn E | Proposed Sale | 10,000 | $240.15 | $2.4M | — | View → |
| Feb 27, 2026 | Mar 3 9:21 PM | Robert J DeckerVP Corporate Controller | Sale | 4,075 | $247.87 | $1.0M | 23,682(D) | View → |
| Feb 27, 2026 | Feb 27 7:35 PM | Decker Robert J | Proposed Sale | 4,075 | $247.87 | $1.0M | — | View → |
| Feb 20, 2026 | Feb 23 10:20 PM | Timothy SchmidEVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $324.8K | 25,447(D) | View → |
| Feb 20, 2026 | Feb 20 3:46 PM | Schmid Timothy | Proposed Sale | 1,322 | $245.66 | $324.8K | — | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | James D. SwansonEVP, CIO | Sale | 20,521 | $242.70 | $5.0M | 25,698.131(D) | View → |
| Feb 13, 2026 | Feb 19 2:12 AM | James D. SwansonEVP, CIO | Sale | 41,559 | $243.73 | $10.1M | 25,020.131(D) | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | Joseph J WolkExec VP, CFO | Sale | 89,654 | $242.80 | $21.8M | 14,000(D) | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Sale | 53,931 | $243.00 | $13.1M | 10,658(D) | View → |
| Feb 18, 2026 | Feb 19 2:11 AM | Timothy SchmidEVP, WW Chair, MedTech | Sale | 22,623 | $244.33 | $5.5M | 26,769(D) | View → |
| Feb 17, 2026 | Feb 19 2:11 AM | Vanessa BroadhurstEVP, Global Corp Affairs | Sale | 6,197 | $243.39 | $1.5M | 23,003(D) | View → |
Page 1 of 2
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | Feb 19 2:12 AM | Robert J DeckerVP Corporate Controller | Option Exercise | 3,053 | — | 0(D) | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Option Exercise | 51,648 | $157.92 | 59,854(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Option Exercise | 3,196 | — | 3,692(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Grant/Award | 52,928 | $243.45 | 3,546(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Elizabeth ForminardEVP, Chief Legal Officer | Grant/Award | 29,020 | $243.45 | 1,944(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Elizabeth ForminardEVP, Chief Legal Officer | Option Exercise | 2,024 | — | 2,126(D) | View → |
| Feb 13, 2026 | Feb 19 2:11 AM | Elizabeth ForminardEVP, Chief Legal Officer | Option Exercise | 14,357 | — | 0(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Jennifer L TaubertEVP, WWC. Innovative Medicine | Grant/Award | 58,809 | $243.45 | 3,940(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Jennifer L TaubertEVP, WWC. Innovative Medicine | Option Exercise | 3,441 | — | 3,692(D) | View → |
| Feb 13, 2026 | Feb 19 2:11 AM | Jennifer L TaubertEVP, WWC. Innovative Medicine | Option Exercise | 28,714 | — | 0(D) | View → |
| Feb 18, 2026 | Feb 19 2:11 AM | Timothy SchmidEVP, WW Chair, MedTech | Option Exercise | 22,623 | $129.51 | 0(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Timothy SchmidEVP, WW Chair, MedTech | Grant/Award | 38,037 | $243.45 | 2,548(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Timothy SchmidEVP, WW Chair, MedTech | Option Exercise | 2,054 | — | 2,051(D) | View → |
| Feb 13, 2026 | Feb 19 2:11 AM | Timothy SchmidEVP, WW Chair, MedTech | Option Exercise | 4,877 | — | 0(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Joaquin DuatoDirector, CEO and Chairman of the Board | Grant/Award | 141,193 | $243.45 | 9,459(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Joaquin DuatoDirector, CEO and Chairman of the Board | Option Exercise | 8,187 | — | 9,008(D) | View → |
| Feb 13, 2026 | Feb 19 2:11 AM | Joaquin DuatoDirector, CEO and Chairman of the Board | Option Exercise | 76,523 | — | 0(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Vanessa BroadhurstEVP, Global Corp Affairs | Grant/Award | 15,439 | $243.45 | 1,034(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Vanessa BroadhurstEVP, Global Corp Affairs | Option Exercise | 1,018 | — | 1,050(D) | View → |
| Feb 13, 2026 | Feb 19 2:11 AM | Vanessa BroadhurstEVP, Global Corp Affairs | Option Exercise | 9,002 | — | 0(D) | View → |